Combination treatment with coenzyme Q10 and simvastatin in patients with coronary atherosclerosis

Kardiologiya

Volumn 46, Issue 8, 2006, Pages 11-13

  Chapidze, G E ^a   Kapanadze, S D ^a   Dolidze, N K ^a   Latsabidze, N E ^a   Bakhutashvili, Z V ^a  

^a Center for Critical Cardiology   (Georgia)

Author keywords

Coenzyme Q10; Coronary atherosclerosis; Lipid peroxidation; Nitric oxide; Platelet aggregation

Indexed keywords

ANTIOXIDANT; DRUG DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID PEROXIDE; NITRIC OXIDE; SIMVASTATIN; UBIDECARENONE; UBIQUINONE;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD; CELL PROTECTION; COMPARATIVE STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DRUG COMBINATION; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; MALE; MIDDLE AGED; OXIDATIVE STRESS; RADIOGRAPHY; TREATMENT OUTCOME;

ADULT; AGED; ANTIOXIDANTS; CORONARY ANGIOGRAPHY; CORONARY ARTERIOSCLEROSIS; CYTOPROTECTION; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPID PEROXIDES; MALE; MIDDLE AGED; NITRIC OXIDE; OXIDATIVE STRESS; SIMVASTATIN; TREATMENT OUTCOME; UBIQUINONE;

EID: 33750220559     PISSN: 00229040     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Biancari F., Lathinen J., Lepojarvi S. et al. Preoperative C-reactive protein and outcome after coronary bypass surgery. Ann Thorac Surg 2003;76:2007-2012.
2. Ngaage D.L. Off pump coronary artery bypass grafting: the myth, the logic and the science. Eur J Cardiothorac Surg 2003;24:557-570.
3. Hadjinikolaou L., Alexiou C., Cohen A.S. et al. Early changes in plasma antioxidant and lipid peroxidation level following coronary artery bypass surgery: a complex response. Eur J Cardiothorac Surg 2003;23:969-975.
4. Bliznacow E.G., Wilkins D.J. Biochemical and clinical consequences of inhibiting coenzyme Q10 biosynthesis by lipid-lowering HMG-CoA reductase inhibitors (statins): a critical overview. Adv Ther 1998;15:4:218-228.
5. Mortensen S.A., Leth A., Anger E. et al. Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors. Mol Aspect Med 1997;18:Suppl:S137-S144.
6. Meenakshi K., Alexander B.S., Krichten C.M. et al. The effect of coenzyme Q10 in patients with congestive heart failure. Ann Intern Med 2000;132:636-640.
7. Silver M., Langsjoen P., Szabo S. et al. Effect of atorvastatin on left ventricular diastolic function and ability of coenzyme Q10 to reverse that dysfunction. Am J Cardiol 2004;94:1306-1310.
8. Gotto A.M. Low high-density lipoprotein cholesterol as a risk factor in coronary heart disease. Circulation 2001;103:2213-2218.
9. Grundy S.M., Cleeman J.I., Merz N.B. et al. Implications of recent clinical trials for the National Cholesterol Education program adult treatment panel III guidelines. Circulation 2004;110:227-239.
10. Buffon A., Santini S.A., Ramazzotti V. et al. Large, sustained cardiac lipid peroxidation and reduced antioxidant capacity in the coronary circulation after brief episodes of myocardial ischemia. Circulation 2000;35:633-639.
11. Heitzer T., Schlinzig T., Krohn K. et al. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001;104:2673-2685.
12. Bonetti P.O., Lerman L.O., Lerman A. Endothelial dysfunction a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol 2003;23:168-182.